Showing results (191-200 of 605) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|April 7, 2018
Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression MethodsRalph Crott
Pharmacoeconomics - Open|April 7, 2018
Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in NigeriaMaxwell Ogochukwu Adibe, Chibueze Anosike, Sunday Odunke Nduka, et al.
Pharmacoeconomics - Open|April 7, 2018
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014David Nathanson, Ugne Sabale, Jan W Eriksson, et al.
Pharmacoeconomics - Open|April 20, 2018
Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide InitiationSteven P Kennedy, Hanna Iaizzo, Evgueni Fayn, et al.
Pharmacoeconomics - Open|May 17, 2022
Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United KingdomMehdi Javanbakht, Atefeh Mashayekhi, Angeline Carlson, et al.
Pharmacoeconomics - Open|March 11, 2020
Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy TrialsKatherine Dick, Andrew Briggs, Henrik Brandi
Pharmacoeconomics - Open|March 14, 2020
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UKBernd Schweikert, Chiara Malmberg, Örjan Åkerborg, et al.
Pharmacoeconomics - Open|January 6, 2021
Health Economic Evidence of Point-of-Care Testing: A Systematic ReviewDeon Lingervelder, Hendrik Koffijberg, Ron Kusters, et al.
Pharmacoeconomics - Open|November 13, 2021
Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in JordanImad Treish, Abeer Al Rabayah, Saad Jaddoua, et al.
Pharmacoeconomics - Open|November 11, 2021
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or EnzalutamideDikshyanta Rana, Claudia Geue, Kelly Baillie, et al.
Pageof 61